DK2470545T3 - Anhydrate former af et pyridinderivat - Google Patents
Anhydrate former af et pyridinderivatInfo
- Publication number
- DK2470545T3 DK2470545T3 DK10747619.4T DK10747619T DK2470545T3 DK 2470545 T3 DK2470545 T3 DK 2470545T3 DK 10747619 T DK10747619 T DK 10747619T DK 2470545 T3 DK2470545 T3 DK 2470545T3
- Authority
- DK
- Denmark
- Prior art keywords
- pyridine derivative
- anhydrate forms
- anhydrate
- forms
- pyridine
- Prior art date
Links
- 150000003222 pyridines Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23743509P | 2009-08-27 | 2009-08-27 | |
| PCT/EP2010/062420 WO2011023733A1 (en) | 2009-08-27 | 2010-08-25 | Anhydrate forms of a pyridine derivative |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2470545T3 true DK2470545T3 (da) | 2014-01-13 |
Family
ID=42790943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10747619.4T DK2470545T3 (da) | 2009-08-27 | 2010-08-25 | Anhydrate former af et pyridinderivat |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8796269B2 (enExample) |
| EP (1) | EP2470545B1 (enExample) |
| JP (3) | JP2013503134A (enExample) |
| KR (1) | KR20120056258A (enExample) |
| CN (1) | CN102639536B (enExample) |
| AU (1) | AU2010288502B2 (enExample) |
| CA (1) | CA2772168C (enExample) |
| DK (1) | DK2470545T3 (enExample) |
| EA (1) | EA021411B1 (enExample) |
| ES (1) | ES2440938T3 (enExample) |
| IL (1) | IL217922A (enExample) |
| IN (1) | IN2012DN01292A (enExample) |
| MX (1) | MX2012002369A (enExample) |
| PL (1) | PL2470545T3 (enExample) |
| SG (1) | SG178231A1 (enExample) |
| WO (1) | WO2011023733A1 (enExample) |
| ZA (1) | ZA201200812B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2440938T3 (es) * | 2009-08-27 | 2014-01-31 | Nerre Therapeutics Limited | Formas anhidrato de un derivado de piridina |
| US10314835B2 (en) | 2014-06-25 | 2019-06-11 | Emory University | Methods of managing conditioned fear with neurokinin receptor antagonists |
| AU2016264034B2 (en) * | 2015-05-18 | 2020-03-05 | KaNDy Therapeutics Limited | Dual NK-1/NK-3 receptor antagonists for the treatment of sex-hormone-dependent diseases |
| AU2017376900A1 (en) * | 2016-12-15 | 2019-05-23 | Glaxosmithkline Intellectual Property Development Limited | NRF2 compounds |
| EA202092131A1 (ru) | 2018-03-14 | 2020-11-27 | Кэнди Терапьютикс Лимитед | Новый фармацевтический препарат, содержащий двойные антагонисты рецептора nk-1/nk-3 |
| WO2021030335A1 (en) * | 2019-08-12 | 2021-02-18 | Millendo Therapeutics, Inc. | A stereoisomerically pure nk-3 receptor antagonist and crystalline forms thereof |
| EP4058433A1 (en) | 2019-11-15 | 2022-09-21 | KaNDy Therapeutics Limited | New chemical process for making 6-chloro-4-(4-fluoro-2-methylphenyl)pyridin-3-amine a key intermediate of nt-814 |
| EP4431512A1 (en) | 2023-03-16 | 2024-09-18 | Bayer Consumer Care AG | Novel dual nk-1/nk-3 receptor antagonists |
| WO2025242584A1 (en) | 2024-05-24 | 2025-11-27 | Bayer Consumer Care Ag | A stable soft gelatin capsule formulation for elinzanetant |
| WO2025242583A1 (en) | 2024-05-24 | 2025-11-27 | Bayer Consumer Care Ag | Novel formulation comprising elinzanetant in a solid dispersion |
| WO2025242585A1 (en) | 2024-05-24 | 2025-11-27 | Bayer Consumer Care Ag | Crystalline forms of salts of elinzanetant and compositions containing salts of elinzanetant |
| TW202604529A (zh) * | 2024-06-18 | 2026-02-01 | 瑞士商拜耳保健消費品股份有限公司 | 用於製造依林奈坦(elinzanetant)前驅物之改良方法 |
| US12533358B1 (en) | 2025-05-14 | 2026-01-27 | Bayer Consumer Care Ag | Methods of treatment with elinzanetant |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1035115B1 (en) * | 1999-02-24 | 2004-09-29 | F. Hoffmann-La Roche Ag | 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists |
| GB0203022D0 (en) * | 2002-02-08 | 2002-03-27 | Glaxo Group Ltd | Chemical compounds |
| HRP20050664A2 (en) * | 2003-01-31 | 2006-12-31 | F. Hoffmann - La Roche Ag | NEW CRYSTALLINE MODIFICATION OF 2-(3,5-BIS-TRIFLUOROMETHYL-PHENYL)-N-[6-(1,1-DIOXO-1λ6-THIOMORPHOLIN-4-YL)-A(4-FLUORO-2-METHYL-PHENYL)-PYRIDIN-3-YL]-N-METHYL-ISOBUTYRAMIDE |
| ES2291891T3 (es) * | 2003-07-03 | 2008-03-01 | F. Hoffmann-La Roche Ag | Antagonistas duales de nk1/nk3 para tratamiento de esquizofrenia. |
| DK1928886T3 (da) * | 2005-09-09 | 2011-07-11 | Glaxosmithkline Llc | Pyridin-derivater og deres anvendelse i behandlingen af psykotiske lidelser |
| AU2008346110A1 (en) * | 2007-12-11 | 2009-07-16 | Cipla Ltd. | Crystalline polymorphic forms of zopiclone, processes for their preparation and their pharmaceutical compositions |
| GB0814340D0 (en) * | 2008-08-05 | 2008-09-10 | Smithkline Beecham Corp | Anhydrous crystol form fo a pyridine derivative |
| ES2440938T3 (es) * | 2009-08-27 | 2014-01-31 | Nerre Therapeutics Limited | Formas anhidrato de un derivado de piridina |
| JP6342662B2 (ja) * | 2014-01-29 | 2018-06-13 | 京セラ株式会社 | ドリルおよびそれを用いた切削加工物の製造方法 |
-
2010
- 2010-08-25 ES ES10747619.4T patent/ES2440938T3/es active Active
- 2010-08-25 SG SG2012007464A patent/SG178231A1/en unknown
- 2010-08-25 EP EP10747619.4A patent/EP2470545B1/en active Active
- 2010-08-25 US US13/389,525 patent/US8796269B2/en active Active
- 2010-08-25 AU AU2010288502A patent/AU2010288502B2/en active Active
- 2010-08-25 EA EA201270302A patent/EA021411B1/ru not_active IP Right Cessation
- 2010-08-25 JP JP2012526048A patent/JP2013503134A/ja active Pending
- 2010-08-25 CA CA2772168A patent/CA2772168C/en active Active
- 2010-08-25 IN IN1292DEN2012 patent/IN2012DN01292A/en unknown
- 2010-08-25 WO PCT/EP2010/062420 patent/WO2011023733A1/en not_active Ceased
- 2010-08-25 MX MX2012002369A patent/MX2012002369A/es active IP Right Grant
- 2010-08-25 CN CN201080037918.3A patent/CN102639536B/zh active Active
- 2010-08-25 KR KR1020127004865A patent/KR20120056258A/ko not_active Ceased
- 2010-08-25 PL PL10747619T patent/PL2470545T3/pl unknown
- 2010-08-25 DK DK10747619.4T patent/DK2470545T3/da active
-
2012
- 2012-02-02 IL IL217922A patent/IL217922A/en active IP Right Grant
- 2012-02-02 ZA ZA2012/00812A patent/ZA201200812B/en unknown
-
2015
- 2015-07-13 JP JP2015139845A patent/JP6404186B2/ja active Active
-
2017
- 2017-06-09 JP JP2017114602A patent/JP2017193564A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US8796269B2 (en) | 2014-08-05 |
| PL2470545T3 (pl) | 2014-03-31 |
| IN2012DN01292A (enExample) | 2015-06-05 |
| EA021411B1 (ru) | 2015-06-30 |
| EP2470545A1 (en) | 2012-07-04 |
| IL217922A0 (en) | 2012-03-29 |
| EA201270302A1 (ru) | 2012-07-30 |
| US20120157450A1 (en) | 2012-06-21 |
| CA2772168C (en) | 2019-01-08 |
| ES2440938T3 (es) | 2014-01-31 |
| BR112012003435A2 (pt) | 2016-02-23 |
| WO2011023733A1 (en) | 2011-03-03 |
| KR20120056258A (ko) | 2012-06-01 |
| AU2010288502B2 (en) | 2013-12-12 |
| ZA201200812B (en) | 2013-03-27 |
| IL217922A (en) | 2016-06-30 |
| JP2013503134A (ja) | 2013-01-31 |
| JP2017193564A (ja) | 2017-10-26 |
| EP2470545B1 (en) | 2013-10-09 |
| CN102639536B (zh) | 2015-03-18 |
| CN102639536A (zh) | 2012-08-15 |
| JP2016000739A (ja) | 2016-01-07 |
| MX2012002369A (es) | 2012-03-29 |
| JP6404186B2 (ja) | 2018-10-10 |
| SG178231A1 (en) | 2012-03-29 |
| CA2772168A1 (en) | 2011-03-03 |
| AU2010288502A1 (en) | 2012-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LTPA2021505I1 (lt) | Pakeistojo policiklinio karbamoilpiridono darinio provaistas | |
| HUS2000005I1 (hu) | Diamino-heterociklusos karboxamid-vegyület | |
| EP2404918A4 (en) | pyridine | |
| EP2519522A4 (en) | SUBSTITUTED IMIDAZOPYRIDINYL-AMINOPYRIDINE COMPOUNDS | |
| IL217922A0 (en) | Anhydrate forms of a pyridine derivative | |
| DK2262793T3 (da) | Krystallinske former af nilotinib-hci | |
| HRP20180646T1 (hr) | Dispiropirolidinski derivat | |
| ECSP12011999A (es) | Derivados benzamida sustituidos | |
| DK2268160T3 (da) | Emulsioner omfattende et PEG-derivat af tokoferol | |
| DK3703369T3 (da) | Fusion af prøveområder | |
| FI20095666A0 (fi) | Hitsauksen optimointi | |
| BRPI1011683A2 (pt) | derivado isoquinolina substituída | |
| DK2404485T3 (da) | Automatisk konfigurering af en belysning | |
| DK2260153T3 (da) | Brandbeskyttelse af et strukturelt element | |
| EP2433940A4 (en) | SPIROIMIDAZOLONDERIVAT | |
| EP2508513A4 (en) | 2-PYRIDONES COMPOUNDS | |
| EP2397480A4 (en) | DIAZEPINEDIONEDERIVATE | |
| EP2648516A4 (en) | SUBSTITUTED PYRIDINONE PYRIDINYL COMPOUNDS | |
| BR112012005960A2 (pt) | n-fenil-1-(4-piridinil)-1h-pirazol-3-aminas substituídas | |
| BR112012002807A2 (pt) | derivados de 5-flúor-2-oxopirimidina-1(2h)-caboxilato | |
| DK2358714T3 (da) | Alkylcyclohexylethere af dihydrotetraazabenzoazulener | |
| SMT201500268B (it) | Derivato di 5-idrossipirimidin-4-carbossammide | |
| EP2401281A4 (en) | PYRIMIDINPYRIMIDOINDAZOLDERIVAT | |
| DK2217006T3 (da) | Et høreapparat | |
| EP2519519A4 (en) | Substituted Naphthalenyl-pyrimidine compounds |